Core Insights - vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment [1][3] - The company will participate in the 38th Annual ROTH Conference, conducting a fireside chat and 1x1 investor meetings from March 22-24, 2026 [1][2] Company Overview - vTv Therapeutics specializes in oral, small molecule drug candidates aimed at treating diabetes and other chronic diseases, with cadisegliatin leading its clinical pipeline [3] - The company is investigating multiple molecules across various indications for chronic diseases [3] Product Details - Cadisegliatin (TTP399) is an oral small molecule, liver-selective glucokinase activator being studied in the US as a potential first-in-class treatment for type 1 diabetes [4] - In non-clinical studies, cadisegliatin has shown the ability to increase glucokinase activity independently from insulin, suggesting potential for improved glycemic control [4] - The product has received Breakthrough Therapy designation from the U.S. FDA, indicating its significance in treatment [4]

Company Overview - vTv Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on developing therapies for Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and other chronic conditions [1]. Key Product - The flagship candidate of the company is Cadisegliatin (TTP399), which is an oral glucokinase activator [1].

Company Overview - vTv Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on developing therapies for Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and other chronic conditions [1]. Key Product - The flagship candidate of the company is Cadisegliatin (TTP399), which is an oral glucokinase activator [1].

Core Viewpoint - vTv Therapeutics Inc. is advancing cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, and is actively participating in investor conferences to discuss its developments [1][2]. Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for diabetes and other chronic diseases [2]. - The clinical pipeline is led by cadisegliatin, which is currently in a US Phase 3 trial for type 1 diabetes [2]. Product Details - Cadisegliatin (TTP399) is a novel, liver-selective glucokinase activator being investigated as an oral adjunctive treatment for type 1 diabetes [3]. - In non-clinical studies, cadisegliatin has shown the ability to increase glucokinase activity independently from insulin, suggesting potential for improved glycemic control [3]. - The product has received Breakthrough Therapy designation from the U.S. FDA, indicating its potential significance in treatment [3].